Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics
Recurrent C. diff study now enrollingAn open-label study of SER-109
Target enrollment achieved in Phase 2b SER-287 study Topline clinical data expected in mid-2021
